Nghiên cứu lâm sàng, cận lâm sàng và mối liên quan giữa sự thay đổi QTc và tình trạng rối loạn chức năng tim ở bệnh nhân ung thư hoá trị bằng Anthracycline

To describe clinical, subclinical characteristics and to investigate the correlation between QTc interval and cardiac dysfunction in cancer patients after one month of Anthracycline therapy. Materials and methods: A cross-sectional descriptive study was conducted on 36 chemotherapy patients with Anthracycline at Can Tho University of Medicine and Pharmacy Hospital and Can Tho Oncology Hospital in 2023. Results: The rates of dyspnea, dry cough, headache, anorexia, and hair loss after one month of Anthracycline treatment were 36,1%, 30,6%, 47,2%, 55,6%, and 58,3%, respectively, compared to 16,7%, 13,9%, 8,3%, 30,6%, and 5,6% before treatment, respectively (p<0,05). Similarly, laboratory parameters after one month of treatment compared to before treatment included red blood cell count (4,4±0,4 vs. 4,5±0,4), hemoglobin (12,3±1,4 vs. 12,9±1,3) (p<0,05), platelet count (426,1±143,1 vs. 343,6±103,3) (p<0,001), and creatinine (66,8±16,7 vs. 62,1±20,6) (p<0,05). Ten subjects had heart dysfunction after 1 month of chemotherapy with Anthracycline (27,8%). The QTc interval increased after one month of Anthracycline treatment compared to pre-treatment in both groups with and without heart dysfunction, but the difference in QTc values before and after treatment is not statistically significant in both groups with and without heart dysfunction. Conclusion: Symptoms after 1 month of Anthracycline chemotherapy (hair loss, loss of appetite, headaches, decreased red blood cell count, increased white blood cell count, and elevated creatinine) are more common compared to before treatment. The QTc interval after 1 month of Anthracycline treatment increases in both groups with and without heart dysfunction, but there is no statistically significant difference in QTc values before and after treatment in either group.